Anasuya Patil Surfactant-Tween

Anasuya Patil Surfactant-Tween


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Pharmaceutical Nanotechnology
Verified
Journal Article
Open access
PDF file
MMMekha Mathew
Mekha Mathew
ASAnasuya Patil Surfactant-Tween
Anasuya Patil Surfactant-Tween
HGHemanth G
Hemanth G
Background: Rheumatoid arthritis is indeed a constant, progressive autoimmune disease that acts on the synovial membrane, distinguished by joint pain, swelling, and tenderness. Sulfasalazine belongs to BCS Class IV having low solubility and low permeability. To overcome the issue and provide a localized effect Cubosomes were chosen for the transdermal drug delivery system. Objective: The primary objective of this investigation was to pass on sulfasalazine-loaded cubosomes over the skin to treat rheumatoid arthritis. On the way to overcome this issue of oral sulfasalazine and provide localized effect, Cubosomes were chosen for the transdermal drug delivery system. Methods: Sulfasalazine-loaded cubosomes were prepared by the top-down method using GMO and Poloxamer 407. Different concentrations of lipid and surfactant were used in the formulation using 32 full factorial designs. The prepared formulations were assessed for p.s, z,p, %EE, FTIR, SEM, invitro release, ex-vivo permeation, and deposition studies with pH 7.4 phosphate buffer saline. Results: The particle size varies between 65 nm to 129 nm, while the negative zeta potential ranged from - 18.8 mV to -24.8 mV. The entrapment efficiency was between 87% and 95%. The formulations' in-vitro drug release was carried out for 12 hours. The optimized formulation showed a controlled release of sulfasalazine and better ex-vivo permeation and deposition properties than sulfasalazine suspension. Conclusion: Overall study findings support the possibility of applying transdermal sulfasalazineloaded cubosomes to alleviate rheumatoid arthritis.

7 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AAAl Amin
Al Amin
TETalha Bin Emran
Talha Bin Emran
JKJishan Khan
Jishan Khan
MZMehrukh Zehravi
Mehrukh Zehravi
ISIndu Sharma
Indu Sharma
Polrat WilairatanaPolrat Wilairatana
Polrat Wilairatana
Cancer is the leading cause of morbidity and mortality in people throughout the world. There are many signaling pathways associated with cancerous diseases, from which the Mitogen-activated protein kinase (MAPK) pathway performs a significant role in this regard. Apoptosis and proliferation are correlated with MAPK signaling pathways. Plenty of experimental investigations were carried out to assess the role of indole alkaloids in MAPK-mediated cancerous diseases. Previous reports established that indole alkaloids, such as vincristine and evodiamine are useful small molecules in cancer treatment via the MAPK signaling system. Indole alkaloids have the anticancer potential through different pathways. Vincristine and evodiamine are naturally occurring indole alkaloids that have strong anticancer properties. Additionally, much research is ongoing or completed with molecules belonging to this group. The current review aims to evaluate how indole alkaloids affect the MAPK signaling pathway in cancer treatment. Additionally, we focused on the advancement in the role of indole alkaloids, with the intention of modifying the MAPK signaling pathways to investigate potential new anticancer small molecules. Furthermore, clinical trials with indole alkaloids in cancer treatment are also highlighted.

2 June 2024
Verified
Book Chapter
Closed access
PDF file
KRKonatham Teja Kumar Reddy
Konatham Teja Kumar Reddy
NVN. Venkatesan
N. Venkatesan
MSM. V. Saranya
M. V. Saranya
Jeevanandham SomasundaramJeevanandham Somasundaram
Jeevanandham Somasundaram
JGJeetendra Kumar Gupta
Jeetendra Kumar Gupta
ASAnasuya Patil Surfactant-Tween
Anasuya Patil Surfactant-Tween

1 January 2025
Verified
Journal Article
Open access
PDF file
ASAnasuya Patil Surfactant-Tween
Anasuya Patil Surfactant-Tween
RBRamenani Babu
Ramenani Babu
VKVivekanand Ankush Kashid
Vivekanand Ankush Kashid
AGAbhilasha Gupta
Abhilasha Gupta
MHMohammed Haneefa
Mohammed Haneefa
VBVivekanand Babu
Vivekanand Babu
Objective: To design and develop sustained-release (SR) glimepiride implants enabling long-term glycemic control with minimized burst release and improved adherence. Methods: Biodegradable PLGA-based in situ forming implants were engineered with solvent-induced phase inversion, using N-methyl-2-pyrrolidone as the primary solvent and polyethylene glycol as a plasticizer to modulate matrix porosity and initial drug efflux. A response-surface design optimized polymer concentration, plasticizer level, and co-solvent ratio to balance burst control and sustained kinetics. Formulations were characterized by SEM, in vitro release profiling over 28 days, and in vivo pharmacokinetics/pharmacodynamics in diabetic rodent models versus oral glimepiride. Results: Increasing PLGA and PEG content reduced surface porosity and attenuated the initial burst while sustaining release, achieving near-zero-order kinetics post-induction. Optimized implants curtailed 2–24h burst and provided depot activity for up to 14 days in vivo, maintaining plasma levels comparable to safe exposures from marketed tablets while prolonging glucose-lowering effects. Embedding glimepiride in nanoparticulate/triblock matrices within PLGA systems further refined release control and depot performance. Design principles and strategies align with contemporary advances in PLGA implant engineering to mitigate burst and enhance completeness of release. Conclusion: Glimepiride SR implants based on optimized PLGA in situ systems offer a feasible depot approach for extended glycemic control, with controlled burst, sustained therapeutic exposure, and potential to improve adherence and outcomes in type 2 diabetes.

23 May 2025 in International Journal of Environmental Sciences
Verified
Journal Article
Open access
PDF file
ASAnasuya Patil Surfactant-Tween
Anasuya Patil Surfactant-Tween
MPmanish patil
manish patil
RRRekha Tarasingh Rajput
Rekha Tarasingh Rajput
MKMohit Kumar
Mohit Kumar
SSSachin Balkrishna Somwanshi
Sachin Balkrishna Somwanshi
RKRitesh Kumar
Ritesh Kumar
Lipid-based nanoformulations have emerged as a promising strategy to enhance the pharmacokinetic profiles and stability of antidiabetic drugs, addressing challenges of poor solubility and bioavailability common among these therapeutics. This research investigates the preparation, characterization, and evaluation of lipid-based nanoparticles, including solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and self-emulsifying drug delivery systems (SEDDS), loaded with various antidiabetic agents. Pharmacokinetic studies demonstrate significant improvements such as increased maximum plasma concentration (Cmax), area under the curve (AUC), and oral bioavailability compared to conventional formulations. Enhanced drug absorption, sustained release, and reduced first-pass metabolism contribute to these outcomes. Stability studies reveal that lipid-based carriers offer superior protection against physical and chemical degradation, maintaining drug integrity under diverse storage conditions including temperature and pH variations. Moreover, lipid excipients improve drug solubility and lymphatic transport, further optimizing therapeutic efficacy. Safety assessments confirm minimal toxicity and good biocompatibility of the formulations. Overall, this study confirms that lipid-based nanoformulations can significantly improve the pharmacokinetic behavior, stability, and therapeutic effectiveness of antidiabetic drugs, supporting their potential as advanced delivery platforms for diabetes management.

1 January 2025
Verified
Journal Article
Open access
PDF file
ASAnasuya Patil Surfactant-Tween
Anasuya Patil Surfactant-Tween
AKAnamika Kulshrestha
Anamika Kulshrestha
SNSuneel Kumar Niranjan
Suneel Kumar Niranjan
PVPayal Nileshbhai Vaja
Payal Nileshbhai Vaja
PKPayal Khamora
Payal Khamora
MTMahesh Madhavrao Thakare
Mahesh Madhavrao Thakare
Worldwide, diabetes mellitus is becoming an increasingly serious health concern. Chronically elevated blood sugar levels due to insulin resistance, insulin ineffectiveness, or, more often than not, both, are the root cause of this condition. Significant macrovascular and microvascular consequences, including as cardiovascular disease, neuropathy, nephropathy, and retinopathy, can develop from this metabolic illness if it is not well controlled. These problems greatly diminish quality of life and raise death rates. To effectively treat diabetes, one must take a comprehensive approach that includes medication, physical activity, and dietary changes in order to keep blood glucose levels within a physiological range. The majority of people with Type 2 Diabetes Mellitus (T2DM) rely on oral hypoglycemic agents (OHAs) as their primary medication. Using the solvent casting process, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, carbopol-934P, and Eudragit RL-100 were utilised to create glipizide mucoadhesive buccal films. The films that were prepared were tested for in vitro residence duration, folding endurance, thickness, surface pH, swelling index, in vitro release, and permeation investigations, among other parameters. with consistent drug content. Over the course of more than six hours, the films demonstrated controlled release. Results showed that films containing 5 mg glipizide in a 4.9% w/v hydroxypropylmethylcellulose and 1.5% w/v sodium carboxymethylcellulose solution swelled adequately, had an ideal residence duration, and showed promise for drug release. Researchers determined that the formulation might be used to create buccal films with therapeutic potential.